Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Gastric cancer (GC) remains a major and potentially fatal malignancy of the stomach, comprising predominantly adenocarcinomas and characterized by substantial geographic variation, heterogeneous molecular biology, and considerable mortality, particularly when diagnosed at an advanced stage. According to Patel et al., in a 2026 review, gastric cancer remains one of the world's most frequently diagnosed and fatal malignancies, with 968,350 new cases and 659,853 deaths estimated globally in 2022; although these are historical burden estimates, the review was published in 2026 and confirms the continuing magnitude of the disease. According to the Gastric Cancer Epidemiology Forecast by Expert Market Research, gastric cancer continues to represent a substantial oncology burden because of its high incidence in East Asia and other high-risk regions, late presentation in many healthcare systems, persistent H. pylori-associated carcinogenesis, and the limited long-term survival associated with metastatic disease.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Gastric Cancer – Number of Cases by Year

Read more about this report - Request a Free Sample

Gastric Cancer Epidemiology Forecast Report Coverage

Expert Market Research's “Gastric Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Gastric Cancer. It projects the future incidence and prevalence rates of Gastric Cancer cases across various populations. The study covers age, gender, and type as major determinants of the Gastric Cancer population. The report highlights patterns in the prevalence of Gastric Cancer overtime and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Gastric Cancer in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Gastric Cancer Understanding: Disease Overview

Gastric cancer (GC) remains a major and potentially fatal malignancy of the stomach, comprising predominantly adenocarcinomas and characterized by substantial geographic variation, heterogeneous molecular biology, and considerable mortality, particularly when diagnosed at an advanced stage. Contemporary literature identifies Helicobacter pylori infection, tobacco exposure, high-salt dietary patterns, alcohol consumption, obesity, premalignant gastric conditions, and inherited susceptibility among important determinants of disease risk. Gastric cancer is also increasingly recognized as a biologically heterogeneous disease involving distinct molecular and histopathological subgroups, with clinically actionable biomarkers including HER2, PD-L1, microsatellite instability/mismatch-repair status, and Claudin-18 isoform 2 (CLDN18.2).

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Older adults, men, individuals infected with H. pylori, smokers, people with high dietary salt exposure, heavy alcohol consumption, obesity, atrophic gastritis or intestinal metaplasia, and individuals with hereditary gastric-cancer susceptibility

Key Diagnostic Method

Upper gastrointestinal endoscopy with histopathological biopsy

Major Risk Factor

Helicobacter pylori infection

Major gap in the market

Late diagnosis, inadequate population-level screening outside high-incidence countries, molecular heterogeneity, resistance to systemic therapy, limited treatment durability in metastatic disease, inconsistent biomarker testing, and the need for more effective perioperative and subsequent-line therapies

Gastric Cancer Epidemiology Perspective

The Gastric Cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Gastric Cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Gastric Cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to the 2026 GBD-based analysis by recent investigators of gastric cancer in China, 1,363,127 prevalent gastric cancer cases were estimated in China in 2023, alongside 575,712 incident cases and 381,500 deaths. This represents one of the largest contemporary country-specific datasets available for gastric cancer and illustrates the substantial prevalence generated by the combination of high incidence and improving survival.

Gender-Specific Cases of the Disease

Gastric cancer continues to demonstrate a clear male predominance. According to Patel et al., the disease is more common in men, consistent with contemporary epidemiological evidence. The 2026 China GBD analysis similarly found that males carried the higher incidence, mortality and prevalence burden. Sex differences are biologically and epidemiologically multifactorial and may reflect differential exposure to smoking, alcohol, occupational factors, hormonal influences and other environmental determinants.

Age-Specific Cases of the Disease

Gastric cancer predominantly affects older adults, with risk increasing substantially with age. Patel et al. reported a median age at diagnosis of approximately 68 years. The contemporary Chinese GBD analysis found that individuals aged 75 years or older carried the highest burden and demonstrated slower reductions in disease rates than younger age groups.

Ethnicity-Wise Cases of the Disease

Gastric cancer demonstrates pronounced geographical and population-level heterogeneity, with substantially higher incidence in East Asian populations and selected regions of Eastern Europe and South America than in many Western populations. Contemporary U.S. SEER data also demonstrate marked racial and ethnic differences: for 2019–2023, the age-adjusted incidence was higher among Hispanic and non-Hispanic Asian/Pacific Islander populations than among non-Hispanic White populations.

Mortality and Survival Analysis of the Disease

Gastric cancer remains associated with substantial mortality because many patients present with locally advanced or metastatic disease. The latest GLOBOCAN 2024 estimates identify stomach cancer as responsible for 6.6% of global cancer deaths, making it one of the leading causes of cancer mortality worldwide. In the United States, contemporary SEER data report a 39.8% five-year relative survival for stomach cancer based on 2016–2022 survival data, while survival remains strongly dependent on stage.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Early / Localized Gastric Cancer

Early gastric cancer is confined to mucosa or submucosa irrespective of lymph-node status and represents an important target for curative treatment. In high-incidence countries with established endoscopic screening, a large proportion of surgically treated cases can be detected at an early stage. The 2023 nationwide Korean Gastric Cancer Association survey reported 63.1% early gastric cancer among 12,751 surgically treated patients

Locally Advanced Gastric Cancer

Locally advanced disease generally involves deeper gastric-wall invasion and/or regional lymph-node involvement without distant metastasis. Multimodal treatment is central to management. Contemporary European guidance continues to identify perioperative FLOT: 5-fluorouracil, leucovorin, oxaliplatin and docetaxel, as a standard regimen for appropriate resectable disease.

Metastatic / Unresectable Gastric Cancer

Metastatic disease constitutes the major high-burden therapeutic population and generally requires systemic treatment rather than curative surgery. Contemporary treatment selection is increasingly biomarker-driven according to HER2, PD-L1, CLDN18.2 and MSI/dMMR status. The 2026 ASCO guideline update recommends biomarker-guided incorporation of immunotherapy and targeted therapies into first-line treatment.

HER2-Positive Gastric Cancer

HER2-positive gastric adenocarcinoma represents a clinically actionable molecular subgroup. Trastuzumab combined with platinum-fluoropyrimidine chemotherapy remains a foundational targeted approach, with pembrolizumab added in appropriate PD-L1-positive disease according to contemporary guideline recommendations.

Gastric Cancer – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Gastric Cancer Epidemiology

The Gastric Cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

Contemporary U.S. SEER data provide robust recent surveillance. The age-adjusted stomach-cancer incidence rate was 7.29 per 100,000 in 2023, while the U.S. mortality rate was 2.60 per 100,000 in 2024. SEER currently estimates 31,510 new stomach-cancer cases and 10,740 deaths in 2026. The 2023 incidence rate is based on official SEER incidence data, while the 2026 case and death figures are modelled estimates.

Germany

Germany remains an important European gastric-cancer market with established endoscopic, surgical and systemic-oncology infrastructure. A 2026 clinical review reports that gastric carcinoma ranks tenth in cancer incidence in Germany, and the contemporary German treatment framework incorporates endoscopic diagnosis, surgical resection, perioperative chemotherapy and biomarker-guided systemic therapy.

France

France has a mature gastric-cancer treatment system and contemporary national clinical guidance covering diagnosis, staging, perioperative treatment and biomarker-guided systemic therapy. The 2026 French intergroup guideline recommends endoscopy and CT for staging, with endoscopic ultrasonography and laparoscopy used selectively, while perioperative FLOT remains the standard for locally advanced resectable disease.

Italy

Italy remains an important European gastric-cancer market because of its established gastrointestinal oncology and surgical infrastructure. Contemporary European practice continues to emphasize endoscopic diagnosis, pathological staging, perioperative chemotherapy and biomarker-driven systemic treatment. Recent evidence evaluating perioperative FLOT in patients treated between 2020 and 2024 found CLDN18.2 positivity in 30.2% of evaluated resectable gastric/GEJ adenocarcinomas, while HER2 positivity was 7.8%; the findings underscore the potential importance of biomarker testing in Italian and broader European practice, although the cohort was not a national epidemiological sample

Spain

Spain represents a significant European gastric-cancer treatment market with established endoscopic, surgical and systemic-oncology capabilities. Contemporary Spanish practice is increasingly influenced by biomarker-directed treatment, particularly HER2, PD-L1, MSI/dMMR and CLDN18.2 testing. The latest European evidence supports perioperative FLOT for locally advanced resectable disease and biomarker-guided systemic treatment for metastatic disease.

United Kingdom

The United Kingdom represents a mature gastric-cancer market with established endoscopic diagnostic pathways, gastrectomy services, chemotherapy, radiotherapy and immunotherapy. Contemporary treatment is increasingly individualized according to HER2, PD-L1, MSI/dMMR and CLDN18.2 status. Recent international guidance supports biomarker-directed immunotherapy and targeted therapy in advanced gastric/GEJ adenocarcinoma. A sufficiently recent nationally representative incidence estimate restricted to 2023–2026 was not identified in the reviewed literature and has therefore not been replaced with an older estimate

Japan

Japan remains one of the world's most important gastric-cancer markets and a major source of contemporary epidemiological and clinical evidence. The 2023 nationwide Korean survey provides a useful regional comparator, demonstrating that 63.1% of surgically treated Korean gastric cancers were early-stage in 2023, while Japan similarly maintains intensive endoscopic detection programs. Contemporary reviews identify routine endoscopic screening in Japan as an important contributor to earlier diagnosis and improved survival.

India

India has a substantial gastric-cancer burden with marked geographical heterogeneity and generally lower population-level screening intensity than Japan or South Korea. Contemporary Indian-authored epidemiological literature continues to identify H. pylori, dietary exposures, smoking, alcohol and premalignant gastric conditions as important risk determinants.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

According to contemporary studies, significant gaps remain in the epidemiological characterization, prevention, early diagnosis, molecular stratification and long-term management of gastric cancer, particularly across countries without organized endoscopic screening or comprehensive Helicobacter pylori control programs. The latest GLOBOCAN 2024 estimates published in 2026 identify stomach cancer as responsible for 4.7% of global incident cancers and 6.6% of cancer deaths, confirming that the disease remains one of the world's major oncological burdens. Contemporary Chinese GBD 2023 estimates further demonstrate the scale of the burden in high-incidence Asia, with 575,712 incident cases, 381,500 deaths and 1,363,127 prevalent cases in 2023. A major opportunity therefore exists in primary prevention and risk-stratified surveillance, particularly through H. pylori detection and eradication, smoking cessation, dietary modification and surveillance of premalignant gastric lesions such as atrophic gastritis and intestinal metaplasia.

Gastric Cancer: Treatment Overview

The management of gastric cancer primarily focuses on achieving complete oncological resection in potentially curable disease, controlling locoregional and metastatic progression, prolonging survival, reducing cancer-related symptoms, preserving nutritional status and maintaining quality of life. Contemporary treatment selection depends on anatomical stage, resectability, histological subtype, performance status, comorbidities and an expanding panel of predictive biomarkers. For very early gastric cancer, endoscopic resection can be appropriate for carefully selected cT1N0 lesions meeting established pathological and technical criteria. For locally advanced resectable disease, surgery is generally integrated with perioperative systemic treatment. The 2026 French intergroup guideline identifies perioperative FLOT: 5-fluorouracil, leucovorin, oxaliplatin and docetaxel: as the standard approach for ≥cT2 and/or node-positive resectable gastric cancer, with endoscopic ultrasound and diagnostic laparoscopy used selectively for staging.

Key Questions Answered

  • What is the current and projected burden of Gastric Cancer across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Gastric Cancer patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Gastric Cancer across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Gastric Cancer across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Gastric Cancer across the 8 major markets?
  • How do major comorbidities and risk factors influence Gastric Cancer epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Gastric Cancer across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Gastric Cancer landscape across the 8 major markets?
  • Which therapeutic areas linked to Gastric Cancer are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Gastric Cancer epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Gastric Cancer epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Gastric Cancer across the 8 major markets?

Scope of the Gastric Cancer Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Gastric Cancer based on several factors.
  • Gastric Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Gastric Cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Advanced Gastric Carcinoma Drug Pipeline Analysis Report

HER Positive Gastric Cancer Drug Pipeline Analysis Report

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us